Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 213 of the 213 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The objective is to formulate clinical practice guidelines for treating Cushing's syndrome. PARTICIPANTS: Participants include an Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. The European Society for Endocrinology co-sponsored the guideline. EVIDENCE: The Task Force used the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews and used the best available evidence from other published systematic reviews and individual studies. CONSENSUS PROCESS: The Task Force achieved consensus through one group meeting, several conference calls, and numerous e-mail communications. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. CONCLUSIONS: Treatment of Cushing's syndrome is essential to reduce mortality and associated comorbidities. Effective treatment includes the normalization of cortisol levels or action. It also includes the normalization of comorbidities via directly treating the cause of Cushing's syndrome and by adjunctive treatments (eg, antihypertensives). Surgical resection of the causal lesion(s) is generally the first-line approach. The choice of second-line treatments, including medication, bilateral adrenalectomy, and radiation therapy (for corticotrope tumors), must be individualized to each patient.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The guidelines provide a general definition of remission after resection of an ACTH-producing corticotroph tumor as morning serum cortisol levels <5 μg/dL (<138 nmol/L) or UFC <28-56 nmol/d (<10-20 μg/d) within 7 days of tumor resection (37).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [37]
In the citing paper
“Steroidogenesis inhibitors work by inhibiting one or more enzymes involved in steroidogenesis, decreasing cortisol and other steroid hormone production (37, 38).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [37]
In the citing paper
“Available medical therapies currently used in clinical practice to treat CS include medications from 3 classes: pituitary-directed therapies (for pituitary CD only), steroidogenesis inhibitors, and glucocorticoid receptor antagonists (37).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [37]
In the citing paper
“In patients with CS, surgical resection of the causative lesion(s) is the first-line treatment option regardless of etiology.”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [37]
In the citing paper
“Pituitary-directed therapies, including pasireotide (US/EU/Canada) and cabergoline (off-label use only), inhibit pituitary ACTH production and, in some cases, ectopic ACTH secretion from neuroendocrine tumors, thereby reducing downstream cortisol secretion (37, 128).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [37]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718 · cited 2×
“(17) 2810 Nieman et al Guidelines on Cushing’s Syndrome Treatment J Clin Endocrinol Metab, August 2015, 100(8):2807–2831”
BackgroundSelf-citationKahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Self-citationPrevention of VTE in Nonorthopedic Surgical Patients
Gould, M. K., Garcia, D. A., Wren, S. M., Karanicolas, P. J., Arcelus, J. I., Heit, J. A., & Samama, C. M. (2012) · Chest · doi:10.1378/chest.11-2297 · Cited by 2,131
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Self-citationMolitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Cushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851
Starkman, M. N., Gebarski, S. S., Berent, S., & Schteingart, D. E. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90079-f · Cited by 840
The natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763
Cited by
Items 101–200 of 1,000
Fleseriu, M., Buchfelder, M., Cetas, J. S., Fazeli, P. K., Mallea-Gil, S., Gurnell, M., McCormack, A. I., Pineyro, M. M., Syro, L. V., Tritos, N. A., et al. (2020) · Pituitary · doi:10.1007/s11102-020-01059-7 · Cited by 64
Paediatric Cushing’s disease: Epidemiology, pathogenesis, clinical management and outcome
Ferrigno, R., Hasenmajer, V., Caiulo, S., Minnetti, M., Mazzotta, P., Storr, H. L., Isidori, A. M., Grossman, A. B., Martino, M. C. D., & Savage, M. O. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09626-4 · Cited by 64
Self-citationLowe, K. M., Young, W. F., Lyssikatos, C., Stratakis, C. A., & Carney, J. A. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000748 · Cited by 61
Losa, M., Mortini, P., Pagnano, A., Detomas, M., Cassarino, M. F., & Giraldi, F. P. (2018) · Endocrine · doi:10.1007/s12020-018-1776-0 · Cited by 61
Factors predicting long-term comorbidities in patients with Cushing's syndrome in remission
Schernthaner-Reiter, M. H., Siess, C., Gessl, A., Scheuba, C., Wolfsberger, S., Riss, P., Knosp, E., Luger, A., & Vila, G. (2019) · Endocrine · doi:10.1007/s12020-018-1819-6 · Cited by 60
Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease
Newell-Price, J., Pivonello, R., Tabarin, A., Fleseriu, M., Witek, P., Gadelha, M. R., Petersenn, S., Tauchmanova, L., Ravichandran, S., Gupta, P., et al. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0695 · Cited by 60
Self-citationCurrent management of Cushing's disease
Tritos, N. A., & Biller, B. M. K. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12975 · Cited by 60
Self-citationUpdates in adrenal steroidogenesis inhibitors for Cushing’s syndrome – A practical guide
Varlamov, E. V., Han, A. J., & Fleseriu, M. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101490 · Cited by 60
Tabarin, A., Assié, G., Barat, P., Bonnet, F., Bonneville, J. F., Borson-Chazot, F., Bouligand, J., Boulin, A., Brue, T., Caron, P., et al. (2022) · Annales d Endocrinologie · doi:10.1016/j.ando.2022.02.001 · Cited by 59
Self-citationValassi, E., Feelders, R., Maiter, D., Chanson, P., Yaneva, M., Reincke, M., Krsek, M., Tóth, M., Webb, S. M., Santos, A., et al. (2018) · Clinical Endocrinology · doi:10.1111/cen.13600 · Cited by 59
Self-citationVarlamov, E. V., Langlois, F., Vila, G., & Fleseriu, M. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1309 · Cited by 58
Petersenn, S., Salgado, L. R., Schopohl, J., Portocarrero-Ortiz, L., Arnaldi, G., Lacroix, A., Scaroni, C., Ravichandran, S., Kandra, A., & Biller, B. M. K. (2017) · Endocrine · doi:10.1007/s12020-017-1316-3 · Cited by 58
Self-citationValassi, E., Franz, H., Brue, T., Feelders, R. A., Netea-Maier, R., Tsagarakis, S., Webb, S. M., Yaneva, M., Reincke, M., Droste, M., et al. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0997 · Cited by 58
Self-citationRowe, N. E., Kumar, R., Schieda, N., Siddiqi, F. S., McGregor, T. B., McAlpine, K., Violette, P. D., Bathini, V., Eng, M. K., & Izard, J. (2023) · The Journal of Urology · doi:10.1097/ju.0000000000003644 · Cited by 59
Doğanşen, S. Ç., Yalın, G. Y., Tanrıkulu, S., Tekin, S., Nizam, N., Bılgıç, B., Sencer, S., & Yarman, S. (2018) · Pituitary · doi:10.1007/s11102-018-0877-3 · Cited by 57
Medical Management of Cushing’s Syndrome: Current and Emerging Treatments
Hinojosa‐Amaya, J. M., Ramos, D. C., & Fleseriu, M. (2019) · Drugs · doi:10.1007/s40265-019-01128-7 · Cited by 57
Therapeutic Strategies for the Treatment of Severe Cushing’s Syndrome
Alexandraki, K., & Grossman, A. B. (2016) · Drugs · doi:10.1007/s40265-016-0539-6 · Cited by 56
Frimodt-Møller, K. E., Jepsen, J. R. M., Feldt‐Rasmussen, U., & Krogh, J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00749 · Cited by 56
Usefulness of 68Ga-Pentixafor PET/CT on Diagnosis and Management of Cushing Syndrome
Ding, J., Tong, A., Hacker, M., Feng, M., Huo, L., & Li, X. (2022) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004244 · Cited by 55
Hawley, J. M., & Keevil, B. G. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.05.014 · Cited by 56
The Role of Isotretinoin Therapy for Cushing’s Disease: Results of a Prospective Study
Vilar, L., Albuquerque, J. L., Lyra, R., Trovão Diniz, E., Rangel Filho, F., Gadelha, P., Thé, A. C., Ibiapina, G. R., Gomes, B. S., Santos, V., et al. (2016) · International Journal of Endocrinology · doi:10.1155/2016/8173182 · Cited by 54
An update on Cushing syndrome in pediatrics
Stratakis, C. A. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.03.010 · Cited by 54
Adrenally Directed Medical Therapies for Cushing Syndrome
Tritos, N. A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa778 · Cited by 54
Cushing’s Syndrome Effects on the Thyroid
Paragliola, R. M., Corsello, A., Papi, G., Pontecorvi, A., & Corsello, S. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063131 · Cited by 54
Pivonello, R., Zacharieva, S., Elenkova, A. P., Tóth, M., Shimon, I., Stigliano, A., Badiu, C., Brue, T. C., Georgescu, C. E., Tsagarakis, S., et al. (2022) · Pituitary · doi:10.1007/s11102-022-01263-7 · Cited by 54
Hypertension and Cardiovascular Mortality in Patients with Cushing Syndrome
Nieman, L. K. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.08.005 · Cited by 52
Self-citationChen, S., Chen, K., Wang, S., Zhu, H., Lü, L., Zhang, X., Tong, A., Pan, H., Wang, R., & Lu, Z. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz194 · Cited by 53
Managing common endocrine disorders amid COVID-19 pandemic
Pal, R., & Bhadada, S. K. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.05.050 · Cited by 52
Perlman, J. E., Johnston, P. C., Hui, F., Mulligan, G., Weil, R. J., Recinos, P. F., Yogi-Morren, D., Salvatori, R., Mukherjee, D., Gallia, G., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab012 · Cited by 50
Acute and Life-threatening Complications in Cushing Syndrome: Prevalence, Predictors, and Mortality
Schernthaner-Reiter, M. H., Siess, C., Micko, A., Zauner, C., Wolfsberger, S., Scheuba, C., Riss, P., Knosp, E., Kautzky-Willer, A., Luger, A., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab058 · Cited by 50
The Adrenal Cortex and its Disorders
Miller, W. L. (2009) · Brook's Clinical Pediatric Endocrinology · doi:10.1002/9781444316728.ch13 · Cited by 50
Cushing's syndrome in the elderly: data from the European Registry on Cushing's syndrome
Amodru, V., Ferrière, A., Tabarin, A., Castinetti, F., Tsagarakis, S., Tóth, M., Feelders, R. A., Webb, S. M., Reincke, M., Netea-Maier, R. T., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad008 · Cited by 50
Self-citationMazziotti, G., Formenti, A., Frara, S., Maffezzoni, F., Doga, M., & Giustina, A. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0860-9 · Cited by 50
Feng, M., Liu, Z., Liu, X., Bao, X., Yao, Y., Deng, K., Xing, B., Lian, W., Zhu, H., Lü, L., et al. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.09.105 · Cited by 50
The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors
Xekouki, P., Brennand, A., Whitelaw, B., Pacák, K., & Stratakis, C. A. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0661-0341 · Cited by 50
Cushing’s disease due to somatic USP8 mutations: a systematic review and meta-analysis
Wanichi, I. Q., Mariani, B. M. P., Frassetto, F. P., Siqueira, S. A. C., Musolino, N. R. D. C., Cunha-Neto, M. B. C., da Silva, G. O., Cescato, V. Â. S., Machado, M. C., Trarbach, E. B., et al. (2019) · Pituitary · doi:10.1007/s11102-019-00973-9 · Cited by 50
Central adrenal insufficiency: open issues regarding diagnosis and glucocorticoid treatment
Ceccato, F., & Scaroni, C. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-0824 · Cited by 49
Fallo, F., Di Dalmazi, G., Beuschlein, F., Biermasz, N. R., Castinetti, F., Elenkova, A., Fassnacht, M., Isidori, A. M., Kastelan, D., Korbonits, M., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003252 · Cited by 49
Self-citationSST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors
Castellnou, S., Vasiljevic, A., Lapras, V., Raverot, V., Alix, E., Borson‐Chazot, F., Jouanneau, E., Raverot, G., & Lasolle, H. (2020) · Endocrine Connections · doi:10.1530/ec-20-0035 · Cited by 49
Role of unilateral adrenalectomy in bilateral adrenal hyperplasias with Cushing’s syndrome
Meloche‐Dumas, L., Mercier, F., & Lacroix, A. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101486 · Cited by 49
Cushing's syndrome: a practical approach to diagnosis and differential diagnoses
Pappachan, J. M., Hariman, C., Edavalath, M., Waldron, J., & Hanna, F. W. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2016-203933 · Cited by 48
Glucocorticoid withdrawal syndrome: what to expect and how to manage
Theiler‐Schwetz, V., & Prete, A. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000804 · Cited by 49
Update on medical treatment for Cushing’s disease
Ramos, D. C., Lim, D. S. T., & Fleseriu, M. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0033-9 · Cited by 49
Long-term outcomes of children treated for Cushing’s disease: a single center experience
Yordanova, G., Martin, L., Afshar, F., Sabin, H. I., Alusi, G., Plowman, N. P., Riddoch, F., Evanson, J., Matson, M. B., Grossman, A. B., et al. (2016) · Pituitary · doi:10.1007/s11102-016-0756-8 · Cited by 47
Self-citationSurgical outcomes in patients with Cushing’s disease: the Cleveland clinic experience
Johnston, P. C., Kennedy, L., Hamrahian, A. H., Sandouk, Z., Bena, J., Hatipoğlu, B., & Weil, R. J. (2017) · Pituitary · doi:10.1007/s11102-017-0802-1 · Cited by 47
Thakur, J. D., Corlin, A., Mallari, R. J., Yawitz, S., Eisenberg, A., Sivakumar, W., Griffiths, C. F., Carrau, R. L., Rettinger, S. R., Cohan, P., et al. (2021) · Pituitary · doi:10.1007/s11102-021-01167-y · Cited by 47
Pituitary Medicine From Discovery to Patient-Focused Outcomes
Melmed, S. K. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3653 · Cited by 47
Park, J., De Luca, A., Dutton, H., Malcolm, J. C., & Doyle, M.-A. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00090 · Cited by 46
Falhammar, H., Calissendorff, J., & Höybye, C. (2016) · Endocrine · doi:10.1007/s12020-016-1127-y · Cited by 46
Valassi, E., Crespo, I., Keevil, B. G., Aulinas, A., Urgell, E., Vives, A. S., Trainer, P. J., & Webb, S. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0779 · Cited by 46
Fleseriu, M., Petersenn, S., Biller, B. M. K., Kadıoğlu, P., Block, C. E. M. D., T'Sjoen, G. G., Vantyghem, M., Tauchmanovà, L., Wojna, J., Roughton, M., et al. (2019) · Clinical Endocrinology · doi:10.1111/cen.14081 · Cited by 46
Self-citationLee, D. H., Park, J. E., Nam, Y. K., Lee, J., Kim, S., Kim, Y., & Kim, H. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-00558-2 · Cited by 46
Bansal, P., Lila, A., Goroshi, M., Jadhav, S., Lomte, N., Thakkar, K., Goel, A., Shah, A., Sankhe, S., Goel, N., et al. (2017) · Endocrine Connections · doi:10.1530/ec-17-0175 · Cited by 45
Fleseriu, M., Biller, B. M. K., Bertherat, J. Y., Young, J., Hatipoğlu, B., Arnaldi, G., O'Connell, P. R., Izquierdo, M. A., Pedroncelli, A. M., & Pivonello, R. (2022) · Pituitary · doi:10.1007/s11102-022-01280-6 · Cited by 45
Self-citationSupportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important
Jin, X., Spampatti, M. P., Spitzweg, C., & Auernhammer, C. J. (2018) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-018-9443-6 · Cited by 45
Pivonello, R., Arnaldi, G., Scaroni, C. M., Giordano, C. S. D. S., Cannavò, S., Iacuaniello, D., Trementino, L., Zilio, M., Guarnotta, V., Albani, A., et al. (2019) · Endocrine · doi:10.1007/s12020-018-1818-7 · Cited by 46
Fan, Y., Liu, Z., Hou, B., Li, L., Liu, X.-H., Liu, Z., Wang, R., Lin, Y., Feng, F., Tian, J., et al. (2019) · European Journal of Radiology · doi:10.1016/j.ejrad.2019.108647 · Cited by 45
Fan, Y., Li, Y., Bao, X., Zhu, H., Lü, L., Yao, Y., Li, Y., Su, M., Feng, F., Feng, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa698 · Cited by 45
The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome
Guarnotta, V., Amato, M. C., Pivonello, R., Arnaldi, G., Ciresi, A., Trementino, L., Citarrella, R., Iacuaniello, D., Michetti, G., Simeoli, C., et al. (2016) · Endocrine · doi:10.1007/s12020-016-0914-9 · Cited by 45
Tanaka, T., Satoh, F., Ujihara, M., Midorikawa, S., Kaneko, T., Takeda, T., Suzuki, A., Sato, M., & Shimatsu, A. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej19-0617 · Cited by 44
“Medical treatment may be varied by coun‐ try, based on the underlying cause of CS [6, 7].”
BackgroundImpact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease
Weigand, I., Knobloch, L., Flitsch, J., Saeger, W., Monoranu, C. M., Höfner, K., Herterich, S., Rotermund, R., Ronchi, C. L., Buchfelder, M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02564 · Cited by 44
Endocrine Causes of Hypertension
de Silva, T., Cosentino, G., Ganji, S. S., Riera-Gonzalez, A., & Hsia, D. S. (2020) · Current Hypertension Reports · doi:10.1007/s11906-020-01108-3 · Cited by 44
Brown, D. R., East, H. E., Eilerman, B., Gordon, M. B., King, E. E., Knecht, L. A., Salke, B., Samson, S. L., Yuen, K. C. J., & Yau, H. (2020) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-020-00105-4 · Cited by 44
Management of NFAs: medical treatment
Even-Zohar, N., & Greenman, Y. (2018) · Pituitary · doi:10.1007/s11102-018-0865-7 · Cited by 43
Therapeutic options after surgical failure in Cushing's disease: A critical review
Rubinstein, G., Oßwald, A., Zopp, S., Ritzel, K., Theodoropoulou, M., Beuschlein, F., & Reincke, M. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.04.004 · Cited by 43
Effectiveness of Medical Treatment of Cushing’s Disease: A Systematic Review and Meta-Analysis
Galendi, J. S. C., Neto, A. N. S. C., Demetres, M. R., Boguszewski, C. L., & Nogueira, V. D. S. N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.732240 · Cited by 43
Management and Medical Therapy of Mild Hypercortisolism
Favero, V., Cremaschi, A., Falchetti, A., Gaudio, A., Gennari, L., Scillitani, A., Vescini, F., Morelli, V., Aresta, C., & Chiodini, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111521 · Cited by 43
Mechanism, diagnosis, and treatment of cyclic Cushing’s syndrome: A review
Cai, Y., Ren, L., Tan, S.-W., Liu, X., Li, C., Gang, X., & Wang, G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113301 · Cited by 43
Lowery, A., Seeliger, B., Alesina, P. F., & Walz, M. K. (2017) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-017-1569-6 · Cited by 43
Broersen, L. H. A., Andela, C. D., Dekkers, O. M., Pereira, A. M., & Biermasz, N. R. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01054 · Cited by 42
Cardiovascular risk and mortality in patients with active and treated hypercortisolism
Li, D., El Kawkgi, O. M., Henriquez, A. F., & Bancos, I. (2020) · Gland Surgery · doi:10.21037/gs.2019.11.03 · Cited by 42
Circadian Biomarkers in Humans: Methodological Insights into the Detection of Melatonin and Cortisol
Skubic, C., Zevnik, U., Nahtigal, K., Dolenc‐Grošelj, L., & Rozman, D. (2025) · Biomolecules · doi:10.3390/biom15071006 · Cited by 42
Cortisol overproduction results from DNA methylation of CYP11B1 in hypercortisolemia
Kometani, M., Yoneda, T., Demura, M., Koide, H., Nishimoto, K., Mukai, K., Gómez-Sánchez, C. E., Akagi, T., Yokota, T., Horike, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11435-2 · Cited by 42
The Impact of Mild Autonomous Cortisol Secretion on Bone Turnover Markers
Athimulam, S., Delivanis, D. A., Thomas, M. A., Young, W. F., Khosla, S., Drake, M. T., & Bancos, I. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa120 · Cited by 43
DeLozier, O. M., Dream, S. Y., Findling, J. W., Carroll, T. B., Evans, D. B., & Wang, T. S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab698 · Cited by 42
Self-citationCarroll, T. B., Javorsky, B. R., & Findling, J. W. (2016) · Endocrine Practice · doi:10.4158/ep161380.or · Cited by 41
Self-citationPerioperative Management of a Patient With Cushing Disease
Varlamov, E. V., Vila, G., & Fleseriu, M. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac010 · Cited by 41
Ishida, A., Shiramizu, H., Yoshimoto, H., Kato, M., Inoshita, N., Miki, N., Ono, M., & Yamada, S. (2022) · Neurosurgery · doi:10.1227/neu.0000000000002109 · Cited by 41
DeFronzo, R. A., Fonseca, V. A., Aroda, V. R., Auchus, R. J., Bailey, T. S., Bancos, I., Busch, R. S., Buse, J. B., Christofides, E. A., Eilerman, B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-1055 · Cited by 43
Self-citationPredictive modeling for pituitary adenomas: single center experience in 501 consecutive patients
Pappy, A. L., Savinkina, A. A., Bicknese, C., Neill, S. G., Oyesiku, N. M., & Ioachimescu, A. G. (2019) · Pituitary · doi:10.1007/s11102-019-00982-8 · Cited by 41
Two Distinctive POMC Promoters Modify Gene Expression in Cushing Disease
Araki, T., Tone, Y., Yamamoto, M., Kameda, H., Ben-Shlomo, A., Yamada, S., Takeshita, A., Yamamoto, M., Kawakami, Y., Tone, M., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab387 · Cited by 41
Individualized medical treatment options in Cushing disease
Gilis‐Januszewska, A., Bogusławska, A., Rzepka, E., Ziaja, W., & Hubalewska–Dydejczyk, A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1060884 · Cited by 41
Iatrogenic adrenal insufficiency in adults
Martin‐Grace, J., Tomkins, M., O’Reilly, M., & Sherlock, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00929-x · Cited by 40
Updates in the Medical Treatment of Pituitary Adenomas
Gheorghiu, M. L., Negreanu, F. A., & Fleseriu, M. (2019) · Hormone and Metabolic Research · doi:10.1055/a-1066-4592 · Cited by 40
Haissaguerre, M., Puerto, M., Nunes, M. L., & Tabarin, A. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0557 · Cited by 40
Self-citationNew types of localization methods for adrenocorticotropic hormone-dependent Cushing’s syndrome
Senanayake, R., Gillett, D., MacFarlane, J., van der Meulen, M., Powlson, A., Koulouri, O., Casey, R. T., Bashari, W. A., & Gurnell, M. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101513 · Cited by 40
Fleseriu, M., Auchus, R. J., Greenman, Y., Zacharieva, S., Geer, E. B., Salvatori, R., Pivonello, R., Feldt‐Rasmussen, U., Kennedy, L., Buchfelder, M., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0506 · Cited by 40
Self-citationTatsi, C., Boden, R., Sinaii, N., Keil, M. F., Lyssikatos, C., Belyavskaya, E., Rosenzweig, S. D., Stratakis, C. A., & Lodish, M. B. (2017) · Pediatric Research · doi:10.1038/pr.2017.278 · Cited by 40
Zoli, M., Staartjes, V. E., Guaraldi, F., Friso, F., Rustici, A., Asioli, S., Sollini, G., Pasquini, E., Regli, L., Serra, C., et al. (2020) · Neurosurgical FOCUS · doi:10.3171/2020.3.focus2060 · Cited by 40
Cristante, J., Lefournier, V., Sturm, N., Passagia, J. G., Gauchez, A. S., Tahon, F., Cantin, S., Chabre, O., & Gay, E. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00333 · Cited by 39
Mifepristone Treatment in Four Cases of Primary Bilateral Macronodular Adrenal Hyperplasia (BMAH)
Cohan, P., East, H. E., Galati, S.-J., Mercado, J. U., Lim, P. J., Lamerson, M., Smith, J. J., Peters, A. L., & Yuen, K. C. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02638 · Cited by 39
Bilateral Adrenal Hyperplasia: Pathogenesis and Treatment
Chevalier, B., Vantyghem, M., & Espiard, S. (2021) · Biomedicines · doi:10.3390/biomedicines9101397 · Cited by 40
Wu, Y., Gao, L., Guo, X., Wang, Z., Lian, W., Deng, K., Lü, L., Xing, B., & Zhu, H. (2019) · Pituitary · doi:10.1007/s11102-019-00939-x · Cited by 39
Broersen, L. H. A., van Haalen, F. M., Biermasz, N. R., Lobatto, D. J., Verstegen, M. J. T., van Furth, W. R., Dekkers, O. M., & Pereira, A. M. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1038-0 · Cited by 40
Early recognition of aggressive pituitary adenomas: a single-centre experience
Ceccato, F., Regazzo, D., Barbot, M., Denaro, L., Emanuelli, E., Borsetto, D., Rolma, G., Alessio, L., Gardiman, M. P., Lombardi, G., et al. (2017) · Acta Neurochirurgica · doi:10.1007/s00701-017-3396-5 · Cited by 38
Arioli, F., Gamberini, M. C., Pavlović, R., Cesare, F. D., Draghi, S., Bussei, G., Mungiguerra, F., Casati, A., & Fidani, M. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-022-04249-3 · Cited by 38
Effect of cabergoline monotherapy in Cushing’s disease: an individual participant data meta-analysis
Palui, R., Sahoo, J., Kamalanathan, S., Kar, S. S., Selvarajan, S., & Durgia, H. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0936-7 · Cited by 38
Jia, W. P., Li, S., Liu, Q., Zhu, Y., Wu, N., Tang, Y., Li, Q., Ren, K., Zhang, Q., Yu, Y., et al. (2018) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0250-6 · Cited by 37
The Treatment of Refractory Pituitary Adenomas
Dai, C., Liu, X.-H., Ma, W., & Wang, R. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00334 · Cited by 37
Solari, D., Pivonello, R., Caggiano, C., Guadagno, E., Chiaramonte, C., Miccoli, G., Cavallo, L. M., De, M. D. B., Colao, A., & Cappabianca, P. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.03.049 · Cited by 37
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-08
- Volume
- 100
- Issue
- 8
- Pages
- 2807-2831
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC4525003
- OpenAlex
- W2127952551
- Semantic Scholar
- 4d26bfff9a2f2ea132ea661d03d84dc8b2293884
- Cited by
- 1,270
- References
- 213
- Citations by year
- 2026: 99 · 2025: 120 · 2024: 104 · 2023: 117 · 2022: 148 · 2021: 169 · 2020: 116 · 2019: 112 · 2018: 116 · 2017: 83 · 2016: 75 · 2015: 6
- FWCI
- 80.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- Cushing's syndrome, hypercortisolism, surgical resection, bilateral adrenalectomy, radiotherapy, corticotropinoma, comorbidity management, treatment selection
- MeSH terms
- Adrenal Gland Neoplasms, Adrenalectomy, Cushing Syndrome, Endocrinology, Humans, Patient Care Planning, Pituitary Neoplasms, Recurrence, Remission Induction, Evidence-Based Medicine, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.